WHERE NEXT GENERATION DESIGN MEETS REAL-WORLD THERAPEUTIC DEVELOPMENT

BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a strategic interest in specific therapeutic areas.

In a campus of  approximately 60 acres, with approximately 650,000 sqf built surface,  the facility is designed to handle conventional small molecules, Biologics and ADCs (from Conjugation to Fill Finish) and very much focused on innovative compounds.

With full containment facility, applying the most advanced and safe technologies, BSP can offer a wide range of services for Pre-Clinical, Clinical and Commercial supply in compliance with the highest Quality requirements.

BSP is positioned as a centre of excellence and a valued strategic partner among those small and large pharma and biotech companies with an advanced outsourcing process for strategic products with a high technological content.

Merck is a leading science and technology company. Its BioReliance® brand is a global leader in biosafety testing and analytical development services for the biopharmaceutical industry. With more than 75 years of innovation in drug safety testing, BioReliance® delivers risk-mitigating, regulatory-compliant solutions that help ensure the safety and quality of the world's therapeutics.

Operating across a global network of state-of-the-art facilities — including a flagship campus in Rockville, Maryland, and a newly opened facility in Darmstadt, Germany — BioReliance® supports clients at every stage of the product lifecycle, from early pre-clinical development through to licensed commercial production. Its comprehensive service portfolio encompasses viral safety and clearance studies, cell bank manufacturing, analytical characterization, lot release testing, and bioassay development, covering a broad range of modalities including monoclonal antibodies, viral vectors, mRNA, lipid nanoparticle formulations, and antibody-drug conjugates.

Backed by deep scientific expertise and a thorough understanding of global regulatory frameworks, BioReliance® acts as a trusted partner to pharmaceutical and biotechnology companies worldwide — providing the rigorous, independent testing data needed to satisfy FDA, EMA, and international regulatory requirements, and to advance life-saving medicines to patients with confidence.

Clean Cells is a GMP-certified, FDA-inspected CRO/CMO specializing in biosafety and quality control for biologics, cell and gene therapies, and advanced therapeutics. We support developers from preclinical research to commercial production, offering GMP-compliant biosafety testing, GMP cell and viral bank production, secure storage solutions, and the development of tailored analysis.

Our analytical expertise includes rapid microbiology (qPCR, BactALert), viral safety assays, identity testing (NGS, qPCR), and purity assessment (HCP, residual DNA, etc.). Visit our booth to discuss how we can help accelerate your regulatory success.

Nona Biosciences is a global biotech company offering end-to-end antibody discovery solutions—from target validation to IND filing. Using proprietary Harbour Mice® technology and advanced screening platforms, we generate fully human antibodies (H2L2 and HCAb formats) to support the development of diverse therapeutic modalities and drive next-generation drug innovation.

Committed to pioneering innovative bioprocess technologies, LePure Biotech provides high-performance bioprocessing membranes, process consumables, equipment, professional validation services and tailored solutions for global biopharmaceutical manufacturing.

Boasting over 15 years of industry expertise, LePure Biotech has served more than 10,000 clients across over 30 countries and regions. Empowered by robust R&D strength and sophisticated manufacturing capabilities, we continuously optimize products and services to deliver superior reliability, higher efficiency and greater client value.

‍

RheoSense is a biotechnology firm headquartered in San Ramon, Calif. The company specializes in creating industry leading viscometers using their groundbreaking VROC technology. This technology, originally released in 2009, was the first new method of measuring viscosity in over 45 years.

The methodology, now called rectangular slit viscometry, is documented in the US Pharmacopeia chapter 914 and makes measuring the viscosity of fluids exponentially more simple and accurate. RheoSense’s patented rectangular slit viscometers use VROC chips equipped with sensors to measure the viscosity of samples as they flow through the chip.

VROC technology is used in fortune 500 companies around the world in their research, development, and quality assurance processes. Notable clients include Pfizer, Johnson & Johnson, Amgen, and Eli Lilly. Since 2001, RheoSense has been reliably releasing new VROC viscometers with increasingly impressive ranges, accuracy, and features.

CEM Corporation is a global leader in peptide synthesis technology, delivering innovative solutions for research, development, and peptide manufacturing. Its portfolio includes automated microwave peptide synthesizers and high-throughput, parallel platforms designed to accelerate workflows, improve peptide quality, and simplify complex synthesis. For manufacturing-scale applications, the Liberty PRO enables efficient scale-up and production of large peptide batches using proven microwave technology. Trusted by leading pharmaceutical, biotechnology, CRO, and academic laboratories worldwide, CEM combines advanced instrumentation, innovative chemistry, and expert application support to help scientists increase productivity, optimize synthesis performance, and advance peptide development from discovery through to large-scale production.